Loading...
XNAS
ARCT
Market cap555mUSD
Oct 08, Last price  
21.13USD
1D
-2.57%
1Q
38.40%
Jan 2017
39.25%
IPO
183.91%
Name

Arcturus Therapeutics Holdings Inc

Chart & Performance

D1W1MN
P/E
—
P/S
4.15
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.47%
Rev. gr., 5y
46.10%
Revenues
138m
-12.27%
00006,138,00020,382,00012,998,00015,753,00020,789,0009,539,00012,359,000205,755,000157,748,000138,389,000
Net income
-81m
L+172.30%
-3,929,000-1,579,000-10,548,000-32,834,000-19,449,000-24,603,000-10,902,000-21,785,000-25,721,000-71,364,000-206,863,0009,349,000-29,725,000-80,941,000
CFO
-60m
L+230.11%
-2,361,000-1,585,000-7,353,000-28,326,000-18,148,000-19,241,000-460,000-20,760,000-6,445,000-42,861,000-135,043,00031,993,000-18,099,000-59,747,000
Dividend
Jan 04, 20130.0085 USD/sh

Profile

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
URL
https://arcturusrx.com/
IPO date
May 22, 2013
Employees
170
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
138,389
-12.27%
157,748
-23.33%
205,755
1,564.82%
Cost of revenue
251,523
247,961
336,873
Unusual Expense (Income)
NOPBT
(113,134)
(90,213)
(131,118)
NOPBT Margin
Operating Taxes
(4)
1,835
1,295
Tax Rate
NOPAT
(113,130)
(92,048)
(132,413)
Net income
(80,941)
172.30%
(29,725)
-417.95%
9,349
-104.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
682
609
411
BB yield
-0.15%
-0.07%
-0.09%
Debt
Debt current
7,104
4,309
60,655
Long-term debt
53,548
51,814
60,432
Deferred revenue
12,604
42,496
20,071
Other long-term liabilities
497
2,804
Net debt
(178,261)
(235,882)
(272,890)
Cash flow
Cash from operating activities
(59,747)
(18,099)
31,993
CAPEX
(648)
(2,901)
(7,726)
Cash from investing activities
(648)
(2,901)
(7,726)
Cash from financing activities
5,418
(24,087)
(2,859)
FCF
(101,428)
(105,561)
(166,112)
Balance
Cash
237,028
292,005
391,883
Long term investments
1,885
2,094
Excess cash
231,994
284,118
383,689
Stockholders' equity
(448,780)
(367,839)
(338,114)
Invested Capital
734,464
719,561
720,877
ROIC
ROCE
EV
Common stock shares outstanding
27,000
26,628
27,093
Price
16.97
-46.18%
31.53
85.91%
16.96
-54.17%
Market cap
458,190
-45.43%
839,581
82.72%
459,497
-52.82%
EV
279,929
603,699
186,607
EBITDA
(109,590)
(87,256)
(129,591)
EV/EBITDA
Interest
767
420
Interest/NOPBT